AbCellera Biologics Inc. (NASDAQ:ABCL) Shares Acquired by Signaturefd LLC

Signaturefd LLC boosted its position in shares of AbCellera Biologics Inc. (NASDAQ:ABCL) by 244.0% in the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 35,659 shares of the company’s stock after purchasing an additional 25,294 shares during the period. Signaturefd LLC’s holdings in AbCellera Biologics were worth $93,000 at the end of the most recent reporting period.

A number of other large investors have also recently added to or reduced their stakes in the stock. NBC Securities Inc. boosted its stake in AbCellera Biologics by 56.0% during the 3rd quarter. NBC Securities Inc. now owns 11,420 shares of the company’s stock valued at $29,000 after acquiring an additional 4,100 shares during the last quarter. Creative Planning bought a new position in shares of AbCellera Biologics in the 3rd quarter worth about $93,000. Green Alpha Advisors LLC lifted its position in shares of AbCellera Biologics by 96.3% in the 3rd quarter. Green Alpha Advisors LLC now owns 48,515 shares of the company’s stock worth $126,000 after buying an additional 23,806 shares during the last quarter. Sanctuary Advisors LLC bought a new position in shares of AbCellera Biologics in the 2nd quarter worth about $314,000. Finally, B. Riley Wealth Advisors Inc. lifted its position in shares of AbCellera Biologics by 104.8% in the 2nd quarter. B. Riley Wealth Advisors Inc. now owns 21,500 shares of the company’s stock worth $64,000 after buying an additional 11,000 shares during the last quarter. 61.42% of the stock is currently owned by institutional investors.

AbCellera Biologics Price Performance

Shares of ABCL opened at $2.89 on Tuesday. AbCellera Biologics Inc. has a one year low of $2.34 and a one year high of $6.05. The company has a 50-day moving average of $2.61 and a two-hundred day moving average of $3.10. The stock has a market cap of $849.82 million, a price-to-earnings ratio of -5.56 and a beta of 0.38.

AbCellera Biologics (NASDAQ:ABCL) last announced its earnings results on Tuesday, August 6th. The company reported ($0.13) EPS for the quarter, topping the consensus estimate of ($0.15) by $0.02. The company had revenue of $7.30 million during the quarter, compared to analysts’ expectations of $10.12 million. AbCellera Biologics had a negative net margin of 463.77% and a negative return on equity of 13.40%. The business’s revenue for the quarter was down 27.7% on a year-over-year basis. During the same period last year, the company posted ($0.11) earnings per share. Analysts anticipate that AbCellera Biologics Inc. will post -0.55 earnings per share for the current year.

Wall Street Analyst Weigh In

Several analysts recently weighed in on the stock. Benchmark downgraded shares of AbCellera Biologics from a “buy” rating to a “hold” rating in a research report on Tuesday, August 20th. KeyCorp reissued an “overweight” rating and set a $5.00 target price (down previously from $7.00) on shares of AbCellera Biologics in a research note on Thursday, July 11th.

About AbCellera Biologics

AbCellera Biologics Inc builds an engine for antibody drug discovery and development. Its engine discovers antibodies from natural immune responses, which are pre-enriched for antibodies. The company’s preclinical products are ABCL635 for metabolic and endocrine conditions; and ABCL575 for atopic dermatitis.